setrusumab 
GtoPdb Ligand ID: 9202
|
Synonyms: BPS 804 | BPS804 | UX-143 | UX143
Compound class:
Antibody
Comment: Setrusumab (BPS-804) is a fully human investigational monoclonal antibody targeting sclerostin (SOST; which is a negative regulator of bone formation), that is intended to improve bone density.
Development of anti-sclerostin antibodies by Novartis is claimed in patent WO2009047356 [2], although we cannot definitively conclude that BPS-804 is claimed within that patent application. The potential of sclerostin as a therapeutic target in bone diseases is reviewed by Lewiecki (2014) [3]. |
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License